Stock Forecast

  Tango Therapeutics, Inc. ( TNGX) Stock. Should you Buy or Sell?    $ 3.73

0.01 (0.27 %)



Tango Therapeutics, Inc. Analysis

Updated on 10-09-2022
Symbol TNGX
Price $3.73
Beta 0.000
Volume Avg. $366.45 thousand
Market Cap $328.39 M
52 Week Range $3.5 - $18.84


Tango Therapeutics, Inc. opened the day at $3.73 which is +'0.27 % on yesterday's close. Tango Therapeutics, Inc. has a 52 week high of $18.84 and 52 week low of $3.5, which is a difference of $15.34. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $328.39 M and total net profit is $37042000 which means the company is trading at 8.87 times profit to market capitalization. Theoretically, if you were to buy Tango Therapeutics, Inc. for $328.39 M, it would take 15 years to get your money back. Tango Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Tango Therapeutics, Inc. Stock Forecast - Is Tango Therapeutics, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreBuy
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio -3.156
Dividend Yiel 0.000
Net Profit Margin -3.413


Valuing Tango Therapeutics, Inc.


Price Book Value Ratio 1.097 Price To Book Ratio 1.097
Price To Sales Ratio 10.771 Price Earnings Ratio -3.156


How liquid is Tango Therapeutics, Inc.


Current Ratio 9.759
Quick Ratio 9.363


Debt


Debt Ratio 0.334 Debt Equity Ratio 0.501
Long Term Debt To Capitalization 0.000 Total Debt To Capitalization 0.000



Latest news about Tango Therapeutics, Inc.


Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be available on-demand starting on Monday, September 12, 2022 at 7:00 AM ET.

Date : 06/09/2022

Tango Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participate in the following upcoming virtual investor conferences in February:

Date : 02/02/2022

Tango Therapeutics' TNG908 IND For Cancer Study Gets Green Signal By FDA

The FDA has cleared Tango Therapeutics Inc's (NASDAQ: TNGX) Investigational New Drug (IND) application for its lead program, TNG908. TNG908 is a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to kill cancer cells with a methylthioadenosine phosphorylase (MTAP) deletion.

Date : 24/01/2022

Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for presentation as virtual posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 7 – 10, 2021. “The preclinical data being presented today highlight the potential applicability of synthetic letha

Date : 30/09/2021





About Tango Therapeutics, Inc.


CEO :
Sector : Healthcare
Industry : Biotechnology

Website : https://www.tangotx.com

Exchange : NASDAQ Global Market

Description :

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.


My Newsletter

Sign Up For Updates & Newsletters